Pei-Yi Su
Overview
Explore the profile of Pei-Yi Su including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ho C, Yang T, Tseng S, Su P
Int Microbiol
. 2024 Jul;
28(3):473-484.
PMID: 38987387
The tellurite toxicity in Haemophilus influenzae and H. parainfluenzae remains unclear. To understand the potential of tellurite as a therapeutic option for these bacteria, we investigated the antimicrobial efficacy of...
2.
Ho C, Chen C, Su P
Arch Microbiol
. 2024 Jun;
206(7):298.
PMID: 38860999
A decreased chloramphenicol susceptibility in Haemophilus influenzae is commonly caused by the activity of chloramphenicol acetyltransferases (CATs). However, the involvement of membrane proteins in chloramphenicol susceptibility in H. influenzae remains...
3.
Ho C, Chen C, Hsieh C, Su P
Eur J Clin Microbiol Infect Dis
. 2023 Oct;
42(12):1499-1509.
PMID: 37906391
Background: Rifampin is a potent chemoprophylactic antibiotic for Haemophilus influenzae infection, and the resistance rate in H. influenzae is low. In this study, we assessed rifampin resistance-related genetic variations in...
4.
Su P, Cheng W, Ho C
BMC Microbiol
. 2023 Jul;
23(1):178.
PMID: 37407940
Background: Non-typeable Haemophilus influenzae (NTHi) has become the major cause of invasive H. influenzae diseases in the post-H. influenzae type b vaccine era. The emergence of multidrug-resistant (MDR) NTHi is...
5.
Cheng W, Shao W, Wen M, Su P, Ho C
J Antimicrob Chemother
. 2023 May;
78(7):1622-1631.
PMID: 37210083
Background: Cefepime and aztreonam are highly efficacious against H. influenzae, and resistant strains are rare. In this study, we isolated cefepime- and aztreonam-nonsusceptible H. influenzae strains and addressed the molecular...
6.
Su P, Yen S, Yang C, Chang C, Lin W, Shih C
J Biomed Sci
. 2022 Jun;
29(1):44.
PMID: 35729569
Background: Hepatitis B virus (HBV) is a major human pathogen worldwide. To date, there is no curative treatment for chronic hepatitis B. The mechanism of virion secretion remains to be...
7.
Zhao M, Su P, Castro D, Tripler T, Hu Y, Cook M, et al.
PLoS Pathog
. 2021 Jun;
17(6):e1009683.
PMID: 34166473
COVID-19 is a global crisis of unimagined dimensions. Currently, Remedesivir is only fully licensed FDA therapeutic. A major target of the vaccine effort is the SARS-CoV-2 spike-hACE2 interaction, and assessment...
8.
Su P, Huang A, Lai C, Lin H, Lin T, Ho C
BMC Microbiol
. 2020 Apr;
20(1):102.
PMID: 32345232
Background: Concern about Haemophilus influenzae infection has been increasing over recent decades. Given the emergence of H. influenzae with severe drug resistance, we assessed the prevalence of as well as...
9.
Chen H, Su P, Kuo S, Lauderdale T, Shih C
Front Microbiol
. 2018 Jul;
9:1440.
PMID: 30002652
The emergence of antibiotic-resistant bacteria has threatened our health worldwide. There is an urgent need for novel antibiotics. Previously, we identified a novel 37-mer antimicrobial peptide (AMP), HBcARD, with broad...
10.
Su P, Yang C, Chu T, Chang C, Chiang C, Tang F, et al.
Sci Rep
. 2016 Dec;
6:38959.
PMID: 27958343
Capsid assembly and stability of hepatitis B virus (HBV) core protein (HBc) particles depend on balanced electrostatic interactions between encapsidated nucleic acids and an arginine-rich domain (ARD) of HBc in...